Yousif Capital Management LLC purchased a new position in shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 1,522 shares of the company's stock, valued at approximately $368,000.
Several other institutional investors have also added to or reduced their stakes in the company. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at $537,000. Blue Trust Inc. acquired a new position in shares of BeOne Medicines during the 2nd quarter worth $210,000. IFP Advisors Inc bought a new stake in shares of BeOne Medicines during the 2nd quarter worth $243,000. Callan Family Office LLC acquired a new stake in BeOne Medicines in the second quarter valued at about $248,000. Finally, Venturi Wealth Management LLC bought a new position in BeOne Medicines in the second quarter valued at about $371,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
ONC has been the topic of several research reports. Barclays started coverage on shares of BeOne Medicines in a report on Thursday, September 18th. They set an "overweight" rating and a $385.00 price target on the stock. Zacks Research upgraded BeOne Medicines from a "hold" rating to a "strong-buy" rating in a research note on Thursday, September 18th. Royal Bank Of Canada raised their price objective on BeOne Medicines from $349.00 to $364.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. Guggenheim boosted their price objective on BeOne Medicines from $350.00 to $365.00 and gave the stock a "buy" rating in a research report on Thursday, August 7th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of BeOne Medicines in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $345.60.
Read Our Latest Report on BeOne Medicines
BeOne Medicines Stock Down 1.1%
Shares of NASDAQ:ONC opened at $310.03 on Friday. The firm has a market cap of $33.98 billion, a P/E ratio of -179.21 and a beta of 0.31. BeOne Medicines Ltd. - Sponsored ADR has a 12-month low of $170.99 and a 12-month high of $355.30. The business has a fifty day simple moving average of $325.72 and a 200 day simple moving average of $280.26. The company has a quick ratio of 1.72, a current ratio of 1.95 and a debt-to-equity ratio of 0.04.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.84 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.36. BeOne Medicines had a negative return on equity of 1.22% and a negative net margin of 3.89%.The company had revenue of $1.32 billion during the quarter, compared to analysts' expectations of $1.24 billion. Analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.
Insider Buying and Selling at BeOne Medicines
In related news, insider Lai Wang sold 5,000 shares of the business's stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $350.06, for a total value of $1,750,300.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 2,665 shares of the company's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $337.00, for a total transaction of $898,105.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 163,484 shares of company stock worth $51,324,146. Company insiders own 6.62% of the company's stock.
BeOne Medicines Profile
(
Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Further Reading
Want to see what other hedge funds are holding ONC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
